Sharma Sourabh, Sanjay Sanjay
Department of Nephrology, VMMC & Safdarjung Hospital, New Delhi, India.
Department of Endocrinology, Bharti Hospital, Karnal, India; University Center for Research & Development, Chandigarh University, Mohali, India.
J Pak Med Assoc. 2025 Feb;75(2):338-339. doi: 10.47391/JPMA.25-13.
Depression is a common and debilitating comorbidity in patients with chronic kidney disease (CKD), particularly those with end-stage kidney disease (ESKD, CKD stage 5). This association stems from a complex interplay of biological and psychosocial factors, including the accumulation of uraemic toxins such as middle molecules, chronic inflammation, and the psychological burden of disease progression. Initiation of dialysis has been observed to alleviate depressive symptoms through multiple mechanisms: removal of uraemic toxins, improvement in physical health, and reduction in psychosocial stressors. This article reviews the pathophysiological underpinnings of depression in CKD, explores the impact of dialysis on depressive symptoms, and evaluates whether depression can be considered a "dialyzable" entity.
抑郁症是慢性肾脏病（CKD）患者中常见且使人衰弱的合并症，尤其是那些患有终末期肾病（ESKD，CKD 5期）的患者。这种关联源于生物和心理社会因素的复杂相互作用，包括中分子等尿毒症毒素的蓄积、慢性炎症以及疾病进展带来的心理负担。已观察到开始透析可通过多种机制减轻抑郁症状：清除尿毒症毒素、改善身体健康状况以及减轻心理社会压力源。本文综述了CKD中抑郁症的病理生理基础，探讨透析对抑郁症状的影响，并评估抑郁症是否可被视为一种“可透析”的病症。
